159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review

Abstract

Background: METex14 skipping is a rare primary oncogenic driver in non-small cell lung cancer (NSCLC). A systematic literature review was conducted to fully evaluate the characteristics of patients with advanced NSCLC with METex14 skipping. Methods: We searched EMBASE, PubMed and selected conferences following the National Institute for Health and Care Excellence guidelines; two independent reviewers assessed the eligibility of articles based on predefined criteria. Search terms identified interventional and non-interventional studies, of any design, reporting outcomes in patients with METex14 skipping NSCLC. Results: A total of 753 abstracts were screened and 130 eligible publications were identified. 37 publications reported the characteristics of patients (n = 1,211) with METex14 skipping NSCLC. Data from 28 publications including 1,108 patients showed a median age of 72.3 years (interquartile range [IQR] of reported medians: 67.1–74.8; range: 64.0–80.5). 45% of patients were male (IQR: 35–61%; range: 0%–88%) and 55% of patients were female (IQR: 39–65%; range: 12–100%) (data from 31 publications/1,086 patients). Patients were more commonly ‘ever smokers’ (55% [IQR: 31–64%; range: 0–80%]) than ‘never smokers’ (40% [IQR: 33–53%; range: 20–78%, excluding outliers]) (data from 21 publications/809 patients). The most commonly reported histologies were adenocarcinoma (79% [IQR: 66–84%; range: 50–100%, excluding outliers]) from 29 publications (950 patients), pulmonary sarcomatoid carcinoma (10% [IQR: 0–33%; range: 0–39%, excluding outliers]) from 18 publications (757 patients), and squamous cell carcinoma (8% [IQR: 0–17%; range: 0–22%, excluding outliers]) from 19 publications (782 patients). Conclusions: Findings from this review help to better characterize this rare patient population, confirming that patients with METex14 skipping NSCLC are typically elderly and that METex14 skipping is found across histologies. This underscores the importance of testing all patients with NSCLC for METex14 skipping alterations in order to receive targeted treatment. Editorial acknowledgement: Medical writing assistance (funded by Merck KGaA, Darmstadt, Germany) was provided by Syneos Health, London, UK. Legal entity responsible for the study: Merck KGaA. Funding: Merck KGaA. Disclosure: J. Mazieres: Advisory/Consultancy: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis. A. Cortot: Research grant/Funding (self): Merck KGaA; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Takeda. B. Pfeiffer: Full/Part-time employment: Merck KGaA. H. Vioix: Full/Part-time employment: Merck KGaA. All other authors have declared no conflicts of interest.